| Bisphosphonates and osteonecrosis of the jaw: a retrospective study. | |
| | |
MedLine Citation:
|
PMID: 17599853 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To assess the prevalence of osteonecrosis of the jaw (ONJ) in patients receiving bisphosphonate therapy and in those who were bisphosphonate naïve. METHODS: We undertook a retrospective review of medical records of patients at the New York Harbor Health Care System from 1999 through 2004. Charts were selected for review if patients had a Current Procedural Terminology (CPT) code suggestive of ONJ or if they had ever received bisphosphonate therapy. RESULTS: Among 1,951 medical records reviewed, we identified 2 patients with ONJ who had received bisphosphonates and 2 patients with ONJ who were bisphosphonate naïve. Both patients treated with bisphosphonates had multiple myeloma and were receiving monthly infusions. They had initially received pamidronate before treatment was changed to zoledronic acid. In each case, ONJ was precipitated by a routine dental extraction. The prevalence of ONJ in our patient population receiving intravenously administered bisphosphonates was 1 in 71.5. Of the 2 cases of ONJ in bisphosphonate-naïve patients, osteoradionecrosis was clearly incriminated in 1 patient and potentially the causative factor in the other patient as well. No patients receiving orally administered bisphosphonates had ONJ, nor did this complication occur in any patients receiving parenteral bisphosphonate therapy for disorders such as osteoporosis or Paget's disease of bone. CONCLUSION: Bisphosphonates remain an important option for management of metabolic bone disease and complications of malignant disease. The overall prevalence of ONJ in patients receiving bisphosphonates seems to be very low; however, patients receiving intense parenteral therapy for an underlying malignant condition appear to have a uniquely elevated risk for the development of this complication. A causal relationship between bisphosphonates and ONJ remains to be proved and merits further investigation. |
| | |
Authors:
|
Omar M Murad; Surender Arora; Amal F Farag; Helena A Guber |
Related Documents
:
|
19364963 - Reticulin accumulation in essential thrombocythemia: prognostic significance and relati... 10091153 - Growth hormone secretion and bone histomorphometric study in thalassaemic patients with... 16551933 - Supraclavicular block in the obese population: an analysis of 2020 blocks. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists Volume: 13 ISSN: 1934-2403 ISO Abbreviation: Endocr Pract Publication Date: 2007 May-Jun |
Date Detail:
|
Created Date: 2007-06-29 Completed Date: 2007-07-19 Revised Date: 2007-10-30 |
Medline Journal Info:
|
Nlm Unique ID: 9607439 Medline TA: Endocr Pract Country: United States |
Other Details:
|
Languages: eng Pagination: 232-8 Citation Subset: IM |
Affiliation:
|
Division of Endocrinology, Elkhart Clinic and Elkhart General Hospital, Elkhart, Indiana. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Aged, 80 and over Alendronate / adverse effects Bone Density Conservation Agents / adverse effects* Bone Diseases / drug therapy Diphosphonates / adverse effects* Etidronic Acid / adverse effects, analogs & derivatives Humans Imidazoles / adverse effects Jaw Diseases / chemically induced* Male Middle Aged Osteonecrosis / chemically induced* Prevalence Retrospective Studies Urban Population |
| Chemical | |
Reg. No./Substance:
|
0/Bone Density Conservation Agents; 0/Diphosphonates; 0/Imidazoles; 105462-24-6/risedronic acid; 118072-93-8/zoledronic acid; 2809-21-4/Etidronic Acid; 40391-99-9/pamidronate; 66376-36-1/Alendronate |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Once-daily insulin glargine versus 6-hour sliding scale regular insulin for control of hyperglycemia...
Next Document: Exaggeration of postprandial hyperglycemia in patients with type 2 diabetes by administration of caf...